Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications

Francesco Maiuri1, Giuseppe Mariniello1, Oreste de Divitiis1

  • 1Neurosurgical Clinic, Department of Neurosciences and Reproductive and Odontostomatological Sciences, Naples, Italy.

Frontiers in Oncology
|August 2, 2021
PubMed
Abstract

Insights

Progesterone receptor (PR) expression in meningiomas correlates with tumor location and time to recurrence. Higher PR expression is linked to slower recurrence, indicating its prognostic value.

Area of Science:

  • Neuro-oncology
  • Pathology
  • Surgical Oncology

Background:

  • Progesterone receptor (PR) expression is a known prognostic factor in meningiomas.
  • Limited data exists on PR expression's correlation with patient age, tumor location, and recurrence patterns.

Purpose of the Study:

  • To investigate the correlation between PR expression and clinical-pathological factors in meningiomas.
  • To analyze the relationship between PR expression and recurrence rates, patterns, and time to recurrence.

Main Methods:

  • Retrospective analysis of 300 meningioma cases.
  • Classification of PR expression into five categories (absent to high).
  • Correlation analysis with patient demographics, tumor characteristics, and recurrence data.

Main Results:

  • Higher PR expression observed in medial skull base and spinal meningiomas.
  • Inverse correlation between PR expression, WHO grade, and Ki-67 MIB1.
  • Lower PR expression in recurrent meningiomas; higher PR expression associated with recurrence >5 years.

Conclusions:

  • PR expression is a significant prognostic marker for meningioma recurrence time.
  • PR expression does not differ between pre/postmenopausal women or recurrence patterns.
  • Routine inclusion of PR assessment in meningioma pathology is recommended for prognostic evaluation.